Sociedad Americana de Hirudoterapia

Lista completa de indicaciones

Catálogo integral de indicaciones documentadas de hirudoterapia con clasificación de evidencia

Last Updated: March 1, 2026Reviewed by: Andrei Dokukin, MDRegulatory Status: FDA-Cleared (Tier 1)

This page catalogs all documented indications for hirudotherapy with regulatory tier classification based on the strength of published evidence and FDA clearance status. Each indication is classified using the ASH three-tier system.

Classification System

Tier A (FDA-Cleared): Supported by FDA 510(k) clearance and systematic review evidence. Tier B (Clinical Evidence): Supported by RCTs or controlled studies; not FDA-cleared. Tier C (Investigational): Documented in international clinical literature (case series, expert experience); requires investigational framing and appropriate disclaimers.

Nivel A — Indicaciones autorizadas por la FDA bajo 510(k)

FDA-Cleared Indication

These are the only indications included in the FDA 510(k) clearance for medicinal leeches.

ConditionEvidenceSpecialtyTier
Venous congestion — microsurgical flap salvageOnly FDA 510(k)-cleared indicationSystematic reviews (n=277, n=407); 78% salvageSurgeryTier A
Venous congestion — digit/tissue replantationIncluded in 510(k) K040187 languageCase series; prophylactic 92% vs reactive 67%SurgeryTier A

Nivel B — Evidencia clínica (no autorizada por la FDA)

Clinical Evidence — Not FDA-Evaluated

These indications are supported by controlled clinical studies but are not included in the FDA 510(k) clearance. Use requires off-label disclosure in informed consent.

ConditionEvidenceSpecialtyTier
Knee osteoarthritisLevel I: Michalsen 2003 (n=51 RCT), Andereya 2008 (n=113 sham-RCT)RheumatologyTier B
Chronic venous insufficiencyLevel III: Multiple comparative cohortsVascularTier B
Acute thrombophlebitisLevel III: n=46+87 comparativeVascularTier B
Post-thrombotic syndromeLevel III: n=87 comparative cohortVascularTier B
Wound healingLevel III: Multiple controlled studiesDermatologyTier B
Pain syndromes (localized)Level I-II: Some RCT data for OA, epicondylitisPain MedicineTier B

Nivel C — En investigación / Evidencia internacional

Investigational / Research Priority

These indications are documented in international clinical literature, primarily case series and expert clinical experience. ASH supports controlled clinical investigation of these applications.

ConditionEvidenceSpecialtyTier
Coronary artery diseaseLevel IV: Case series (n=97, n=530)CardiologyTier C
HypertensionLevel III-IV: Gantimurova 2001 (n=94+20), Baskova cohort (n=42)CardiologyTier C
Congestive heart failureLevel IV: Case series (n=65)CardiologyTier C
Cerebrovascular diseaseLevel III: Comparative cohort (n=197+)NeurologyTier C
Acute angle-closure glaucomaLevel III: n=302 comparativeOphthalmologyTier C
Chronic glaucomaLevel III: n=340 comparativeOphthalmologyTier C
Osteoarthritis (non-knee)Level IV: Case series (n=162)RheumatologyTier C
Sensorineural hearing lossLevel IV: Case series (n=104)OtolaryngologyTier C
SinusitisLevel IV: Case series (n=60)OtolaryngologyTier C
Vasomotor rhinitisLevel IV: Case series (n=55)OtolaryngologyTier C
Inflammatory eye diseaseLevel IV: >300/yr clinical experienceOphthalmologyTier C
Inflammatory gynecological conditionsLevel IV: Case seriesGynecologyTier C
Hepatobiliary diseaseLevel IV: Case seriesGastroenterologyTier C
Endocrine/metabolic conditionsLevel IV: Limited dataEndocrinologyTier C
Dental/oral surgery congestionLevel IV: Case reportsDentistryTier C
Urological inflammatory conditionsLevel IV: Case seriesUrologyTier C
Pediatric applicationsLevel IV: Limited data; relative CI age <6PediatricsTier C

Contraindicaciones absolutas

  • Hemophilia or severe hemorrhagic diatheses
  • Severe anemia (Hb <8 g/dL)
  • Hemodynamic instability
  • Arterial insufficiency at application site
  • Cachexia
  • Documented allergy to leech SGSry gland secretion
  • Patient refusal

Contraindicaciones relativas

  • Concurrent anticoagulant therapy
  • Alcohol intoxication
  • Active fever
  • Pregnancy
  • Immunocompromised state
  • Children under 6 years of age

Interacciones farmacológicas de alto riesgo

Thrombolytics: Absolute Contraindication

Concurrent use of thrombolytic agents with medicinal leech therapy is absolutely contraindicated due to extreme hemorrhagic risk. Other anticoagulants (warfarin, DOACs, heparin) represent high-risk interactions requiring close monitoring.

Recursos relacionados

Clinical Specialties

Evidence organized by medical discipline.

Más información →

Safety & Infection Control

Contraindications, drug interactions, and safety protocols.

Más información →

Regulatory Framework

FDA clearance details and scope of practice.

Más información →

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.